Results 171 to 180 of about 74,932 (226)
Anti-cancer drug design, 1998 The novel furopyrimidine, N-[4-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)-methyl]-methylamino] -benzoyl]-L-glutamate (MTXO), a classical antifolate with weak antitumor activity compared with methotrexate (MTX), has been studied as inhibitorcofactor ternary crystal complexes with recombinant Phe-31 to Ser (F31S) and Phe-31 to Gly (F31G) variant human ...
Vivian Cody +5 more
semanticscholar +5 more sources
Enniatins ofFusariumsp. Strain F31 and Their Inhibition ofBotrytiscinereaSpore Germination
Journal of Natural Products, 2004 A spectrum of enniatins was isolated from Fusarium sp. strain F31 by bioassay-guided isolation directed against Botrytis cinerea. Two new enniatins, J(2) (7) and J(3) (8), were co-isolated and both contained, in addition to three hydroxyisovaleric acid units, N-methylated l-alanine, l-valine, and l-isoleucine units, differing only in their primary ...
Anton Pohanka +5 more
semanticscholar +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Journal of Biological Macromolecules, 2023
In this paper, we reported an excellent hypoglycemic effect of a Ganoderma lucidium polysaccharide F31 with efficacies between 45 and 54 %, approaching to that of liraglutide (52 %). Significantly, F31 reduced the body weight gains and food intakes. F31 decreased 4 key compounds, consisting of adenosine, adenosine, galactitol and glycerophosphocholine ...
Jiaqi, Jiao +13 more
openaire +3 more sources
In this paper, we reported an excellent hypoglycemic effect of a Ganoderma lucidium polysaccharide F31 with efficacies between 45 and 54 %, approaching to that of liraglutide (52 %). Significantly, F31 reduced the body weight gains and food intakes. F31 decreased 4 key compounds, consisting of adenosine, adenosine, galactitol and glycerophosphocholine ...
Jiaqi, Jiao +13 more
openaire +3 more sources
F31 Understanding cognitive heterogeneity beyond disease burden in huntington’s disease [PDF]
Clinical studies, 2018 Background Despite its monogenic cause, the cognitive problems in Huntington’s Disease are heterogeneous. This is particularly pronounced in the premanifest (preHD) stage of the disease. The existing tools cannot explain all of the heterogeneity observed nor can they accurately inform the progression of these aspects of the disease at an individual ...
Wei-Li Kuan +3 more
openaire +2 more sources